Temozolomide News and Research

RSS
Protein activated by inflammation converts glioblastoma multiforme cells to most aggressive form

Protein activated by inflammation converts glioblastoma multiforme cells to most aggressive form

Perrigo Company and Teva Pharmaceutical launch generic equivalent to temozolomide

Perrigo Company and Teva Pharmaceutical launch generic equivalent to temozolomide

Combination therapy with myxoma virus and rapamycin can kill glioblastoma multiforme

Combination therapy with myxoma virus and rapamycin can kill glioblastoma multiforme

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

Study investigates gene expression signature to predict response to bevacizumab

Study investigates gene expression signature to predict response to bevacizumab

Selumetinib demonstrates clinical benefit for patients with metastatic uveal melanoma

Selumetinib demonstrates clinical benefit for patients with metastatic uveal melanoma

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Radiotherapy: First choice treatment for low-grade glioma

Radiotherapy: First choice treatment for low-grade glioma

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

New research offers clues for chemotherapy-induced cognitive impairment

New research offers clues for chemotherapy-induced cognitive impairment

FDA grants orphan drug status to Lentigen’s LG631-CD34 for treatment of glioblastoma multiforme

FDA grants orphan drug status to Lentigen’s LG631-CD34 for treatment of glioblastoma multiforme

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

ICREA researcher updates latest findings in applied epigenetics

ICREA researcher updates latest findings in applied epigenetics

Patients tend to have worse outcomes when GBM appears in more than one location

Patients tend to have worse outcomes when GBM appears in more than one location

New insight into why glioblastoma multiforme recurs in adults

New insight into why glioblastoma multiforme recurs in adults

LSDF announces $570,000 in awards to support commercialization of new health-related products

LSDF announces $570,000 in awards to support commercialization of new health-related products

NCI, Tau Therapeutics open enrollment in mibefradil Phase Ib glioma trial

NCI, Tau Therapeutics open enrollment in mibefradil Phase Ib glioma trial

Radiation oncology researchers revise glioblastoma classification system

Radiation oncology researchers revise glioblastoma classification system